サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：幹細胞治療の市場規模、シェア、動向分析：タイプ別、細胞由来別、治療用途別、地域別展望、競合戦略、2030年までのセグメント別予測
市場調査レポート
商品コード
1089967

幹細胞治療の市場規模、シェア、動向分析：タイプ別、細胞由来別、治療用途別、地域別展望、競合戦略、2030年までのセグメント別予測

Stem Cell Therapy Market Size, Share & Trends Analysis By Type, By Cell source, By Therapeutic Application, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
出版日: | 発行: SPER Market Research Pvt. Ltd. | ページ情報: 英文 271 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.85円
幹細胞治療の市場規模、シェア、動向分析：タイプ別、細胞由来別、治療用途別、地域別展望、競合戦略、2030年までのセグメント別予測
出版日: 2022年06月14日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 271 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の幹細胞治療の市場規模は、今後15.8%のCAGRで拡大し、2030年までに7億19万米ドルに達すると予測されています。幹細胞研究の増加、幹細胞製造のためのGMP認定施設、人工多能性幹細胞に対する需要の高まりなどが市場の促進要因となっています。

当レポートでは、世界の幹細胞治療市場について調査し、市場の概要とともに、タイプ別、細胞由来別、治療用途別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 成長要因、抑制要因、機会、課題の分析
    • 促進要因
    • 抑制要因
    • 市場の機会
    • 課題
  • COVID-19が幹細胞治療市場に及ぼす影響

第5章 市場変数と見通し

  • SWOT分析
  • PESTEL分析
  • ポーターのファイブフォース分析
  • ヒートマップ分析

第6章 世界の幹細胞治療市場、タイプ別、2019年～2030年（100万米ドル）

  • 同種幹細胞治療
  • 自家幹細胞治療

第7章 世界の幹細胞治療市場、細胞由来別、2019年～2030年（100万米ドル）

  • 脂肪組織由来
  • 骨髄由来
  • 胎盤/臍帯由来
  • その他

第8章 世界の幹細胞治療市場、治療用途別、2019年～2030年（100万米ドル）

  • 心血管疾患
  • 炎症性疾患および自己免疫疾患
  • 筋骨格系障害
  • 神経障害
  • その他
  • 手術
  • 創傷・損傷

第9章 世界の幹細胞治療市場、地域別、2019年～2030年（100万米ドル）

  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ

第10章 企業プロファイル

  • AlloSource
  • Anterogen
  • BioRestorative Therapies
  • BrainStorm Cell Therapeutics
  • Cellular Biomedicine Group
  • CORESTEM
  • Holostem Terapie Avanzate Srl
  • Hope Biosciences
  • JCR Pharmaceuticals
  • Kangstem Biotech
  • MEDIPOST
  • Mesoblast
  • NuVasive
  • Orthofix
  • Personalized Stem Cells
  • PHARMICELL
  • Pluristem Therapeutics
  • Regrow Biosciences
  • RTI Surgical
  • Smith & Nephew
  • Stempeutics Research
  • Under Pipeline Athersys
  • Takeda Pharmaceutical Company
  • ViaCyte

第9章 世界の幹細胞治療市場、地域別、2019年～2030年（100万米ドル）

  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ
目次
Product Code: BIOT2233

Global Stem Cell Therapy Market projected to be worth USD 700.19 million by 2030.

According to SPER Market Research, the Stem Cell Therapy Market estimated to reach USD 700.19 million by 2030 with a CAGR of 15.8%. The fuels for the escalation of the Stem Cell Therapy Market are; increasing stem cell research and GMP-certified facilities to manufacture stem cells, rising demand for induced pluripotent stem cells.

Impact of COVID-19 on the Stem Cell Therapy Market

COVID-19 outbreak has a positive impact on the Stem Cell Therapy Market.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030
  • Segments covered: By Type, By Cell Source, By Therapeutic Application, By Region
  • Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa
  • Companies Covered: AlloSource, Anterogen, BioRestorative Therapies, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, CORESTEM, Holostem Terapie Avanzate S.r.l, Hope Biosciences, JCR Pharmaceuticals, Kangstem Biotech, MEDIPOST, Mesoblast, NuVasive, Orthofix, Personalized Stem Cells, PHARMICELL, Pluristem Therapeutics, Regrow Biosciences, RTI Surgical, Smith & Nephew Stempeutics Research, Under Pipeline Athersys, Takeda Pharmaceutical Company, ViaCyte

Driver: funding for stem cell research

Availability of funding for stem cell research, increasing GMP-certification approvals for cell therapy production facilities, increasing clinical trials for stem cell based-therapies; are the key driver for the expansion of this market.

Restraints:

Ethical concerns related to embryonic stem cells, costly cell-based research; are the restraint to the market growth.

Opportunity:

Growing demand for cell & gene therapies, the emergence of induced pluripotent stem cells alternative to embryonic stem cells; provide huge opportunities for the players in the market.

Global Stem Cell Therapy Market, By Type:

Based on the Type, Global Stem Cell Therapy Market is segmented as; Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.

Global Stem Cell Therapy Market, By Cell Source:

Based on the Cell Source, Global Stem Cell Therapy Market is segmented as; Adipose tissue-derived MSCs (mesenchymal stem cells), Bone marrow-derived MSCs, Placental/umbilical cord-derived MSCs, and Other Cell Sources.

Global Stem Cell Therapy Market, By Therapeutic Application:

Based on the Therapeutic Application, Global Stem Cell Therapy Market is segmented as; Cardiovascular Diseases, Inflammatory & Autoimmune Diseases, Musculoskeletal Disorders, Neurological Disorders, Surgeries, Wounds & Injuries, Other Therapeutic Applications.

Global Stem Cell Therapy Market, By Region:

North America owns the biggest share of this Stem Cell Therapy Market; this is due to growing public-private partnership funding, research grants to develop safe & effective stem cell therapy products, and increasing figure of clinical trials.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Stem Cell Therapy Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Stem Cell Therapy Market, By Type, 2019-2030 (USD Million)

  • 6.1. Allogeneic Stem Cell Therapy
  • 6.2. Autologous Stem Cell Therapy

7. Global Stem Cell Therapy Market, By Cell Source, 2019-2030 (USD Million)

  • 7.1. Adipose tissue-derived MSCs (mesenchymal stem cells),
  • 7.2. Bone marrow-derived MSCs,
  • 7.3. Placental/umbilical cord-derived MSCs, and
  • 7.4. Other Cell Sources

8. Global Stem Cell Therapy Market, By Therapeutic Application, 2019-2030 (USD Million)

  • 8.1. Cardiovascular Diseases
  • 8.2. Inflammatory & Autoimmune Diseases
  • 8.3. Musculoskeletal Disorders
  • 8.4. Neurological Disorders,
  • 8.5. Other Therapeutic Applications
  • 8.6. Surgeries,
  • 8.7. Wounds & Injuries

9. Global Stem Cell Therapy Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. AlloSource
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Anterogen
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. BioRestorative Therapies
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. BrainStorm Cell Therapeutics
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Cellular Biomedicine Group
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. CORESTEM
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Holostem Terapie Avanzate S.r.l
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Hope Biosciences
    • 10.7.5. Company details
    • 10.7.6. Financial outlook
    • 10.7.7. Product summary
    • 10.7.8. Recent developments
  • 10.9. JCR Pharmaceuticals
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.10. Kangstem Biotech
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. MEDIPOST
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. Mesoblast
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. NuVasive
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Orthofix
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. Personalized Stem Cells
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. PHARMICELL
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. Pluristem Therapeutics
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. Regrow Biosciences
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. RTI Surgical
    • 10.18.5. Company details
    • 10.18.6. Financial outlook
    • 10.18.7. Product summary
    • 10.18.8. Recent developments
  • 10.20. Smith & Nephew
    • 10.20.1. Company details
    • 10.20.2. Financial outlook
    • 10.20.3. Product summary
    • 10.20.4. Recent developments
  • 10.21. Stempeutics Research
    • 10.21.1. Company details
    • 10.21.2. Financial outlook
    • 10.21.3. Product summary
    • 10.21.4. Recent developments
  • 10.22. Under Pipeline Athersys
    • 10.22.1. Company details
    • 10.22.2. Financial outlook
    • 10.22.3. Product summary
    • 10.22.4. Recent developments
  • 10.23. Takeda Pharmaceutical Company
    • 10.23.1. Company details
    • 10.23.2. Financial outlook
    • 10.23.3. Product summary
    • 10.23.4. Recent developments
  • 10.24. ViaCyte
    • 10.24.1. Company details
    • 10.24.2. Financial outlook
    • 10.24.3. Product summary
    • 10.24.4. Recent developments

9. Global Stem Cell Therapy Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. AlloSource
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Anterogen
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. BioRestorative Therapies
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. BrainStorm Cell Therapeutics
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Cellular Biomedicine Group
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. CORESTEM
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Holostem Terapie Avanzate S.r.l
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Hope Biosciences
    • 10.7.5. Company details
    • 10.7.6. Financial outlook
    • 10.7.7. Product summary
    • 10.7.8. Recent developments
  • 10.9. JCR Pharmaceuticals
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.10. Kangstem Biotech
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. MEDIPOST
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. Mesoblast
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. NuVasive
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Orthofix
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. Personalized Stem Cells
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. PHARMICELL
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. Pluristem Therapeutics
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. Regrow Biosciences
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. RTI Surgical
    • 10.18.5. Company details
    • 10.18.6. Financial outlook
    • 10.18.7. Product summary
    • 10.18.8. Recent developments
  • 10.20. Smith & Nephew
    • 10.20.1. Company details
    • 10.20.2. Financial outlook
    • 10.20.3. Product summary
    • 10.20.4. Recent developments
  • 10.21. Stempeutics Research
    • 10.21.1. Company details
    • 10.21.2. Financial outlook
    • 10.21.3. Product summary
    • 10.21.4. Recent developments
  • 10.22. Under Pipeline Athersys
    • 10.22.1. Company details
    • 10.22.2. Financial outlook
    • 10.22.3. Product summary
    • 10.22.4. Recent developments
  • 10.23. Takeda Pharmaceutical Company
    • 10.23.1. Company details
    • 10.23.2. Financial outlook
    • 10.23.3. Product summary
    • 10.23.4. Recent developments
  • 10.24. ViaCyte
    • 10.24.1. Company details
    • 10.24.2. Financial outlook
    • 10.24.3. Product summary
    • 10.24.4. Recent developments